HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

benzonitrile

Networked: 24 relevant articles (2 outcomes, 5 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Pulkkinen, Juha T: 2 articles (04/2014 - 07/2012)
2. Palvimo, Jorma J: 2 articles (04/2014 - 07/2012)
3. Laatikainen, Reino: 2 articles (04/2014 - 07/2012)
4. Poutiainen, Pekka K: 2 articles (04/2014 - 07/2012)
5. Peräkylä, Mikael: 2 articles (04/2014 - 07/2012)
6. Sheen, Yhun Yhong: 2 articles (11/2011 - 10/2011)
7. Kim, Dae-Kee: 2 articles (11/2011 - 10/2011)
8. Park, Chul-Yong: 2 articles (11/2011 - 10/2011)
9. Hancock, Arthur A: 2 articles (10/2008 - 04/2005)
10. Esbenshade, Timothy A: 2 articles (10/2008 - 04/2005)

Related Diseases

1. Prostatic Neoplasms (Prostate Cancer)
04/25/2014 - "The preclinical profiles of two most potent compounds of our recently published cycloalkane[d]isoxazole pharmacophore-based androgen receptor (AR) modulators, FL442 (4-(3a,4,5,6,7,7a-hexahydro-benzo[d]isoxazol-3-yl)-2-(trifluoromethyl)benzonitrile) and its nitro analog FL425 (3-(4-nitro-3-(trifluoromethyl)phenyl)-3a,4,5,6,7,7a-hexahydrobenzo[d]isoxazole), were explored to evaluate their druggability for the treatment of AR dependent prostate cancer. "
07/26/2012 - "The most potent compound, 4-(3a,4,5,6,7,7a-hexahydrobenzo[d]isoxazol-3-yl)-2-(trifluoromethyl)benzonitrile (6a), exhibits antiandrogenic activity significantly greater than that of the most widely used antiandrogenic prostate cancer drugs bicalutamide (1) and hydroxyflutamide (2) in reporter gene assays measuring the transcriptional activity of AR (decreasing approximately 90% of the total AR activity) and in competitive AR ligand-binding assays (showing over four times higher potency to inhibit radioligand binding in comparison to bicalutamide). "
12/01/1989 - "The effects of 4-hydroxyandrostenedione (4-OHA) and other aromatase inhibitors, 10-propargylestr-4-ene-3,17-dione and imidazo[1,5-alpha]-3,4,5,6-tetrahydropyrin-6-yl-(4-benzonitrile), as well as 5 alpha-reductase inhibitors N,N-diethyl-4-methyl-3-oxo-4-aza-5 alpha-androstane-17 beta-carboxyamide and 4-methyl-3-oxo-4-aza-androsta-5-ene-17-ol were investigated in prostatic tissue from six patients with benign prostatic hypertrophy and seven patients with prostatic cancer, and from normal men at autopsy. "
12/20/1990 - "We recently studied the effects of 4-OHA and other aromatase inhibitors, 10-propargylestr-4-ene-3,17-dione (PED) and imidazo[1,5-alpha]3,4,5,6-tetrahydropyrin-6-yl-(4-benzonitrile) (CGS 16949A) as well as 5 alpha-reductase inhibitors, N,N-diethyl-4-methyl-3-oxo-4-aza-5 alpha-androstane-17 beta-carboxyamide (4-MA) and 17 beta-hydroxy-4-aza-4-methyl-19norandrost-5-en-3-one (L651190) in prostatic tissue from 11 patients with prostatic cancer and six patients with benign prostatic hypertrophy (BPH), and from normal men at autopsy. "
2. Seizures (Seizure)
3. Shock
4. Neoplasms (Cancer)
5. Breast Neoplasms (Breast Cancer)

Related Drugs and Biologics

1. azastene
2. Strychnine
3. bicalutamide (Casodex)
4. hydroxyflutamide
5. Aromatase (CYP19)
6. Xanthine Dehydrogenase
7. YM 511
8. bunitrolol
9. Fadrozole
10. Aromatase Inhibitors